Clinical controversies in the management of candidemia in adults and children

Clicks: 8
ID: 320639
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #57 of 151 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 151 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: Candidemia remains associated with substantial morbidity and mortality despite advances in antifungal therapy, yet multiple aspects of management remain controversial. This review synthesizes emerging evidence to address unresolved clinical dilemmas in candidemia management. SUMMARY: This publication reviews data on optimized antifungal dosing, rapid diagnostic tests (RDTs), antifungal susceptibility testing (AFST), echinocandin-to-azole transition, treatment duration, ophthalmologic screening, echocardiographic evaluation, Candida endocarditis, the place in therapy of rezafungin, antifungal resistance, and dosing considerations in children. Substantial pharmacokinetic variability in critically ill and obese patients supports individualized dosing strategies to reduce underexposure. Echinocandin-to-azole transition after 3 to 5 days appears safe in clinically stable patients with bloodstream sterilization and predicted or confirmed azole susceptibility. Although the standard 14-day duration remains a guideline-supported recommendation, emerging evidence suggesting shorter durations may be feasible in carefully selected patients with truly uncomplicated candidemia. Risk-based approaches to ophthalmologic screening and echocardiography may improve diagnostic stewardship while reducing unnecessary testing. Echinocandins appear at least as effective and safer than amphotericin B for Candida endocarditis. Rezafungin offers a practical once-weekly alternative for select patients requiring prolonged intravenous therapy, although evidence for deep-seated infection remains limited. Increasing resistance among non-albicans Candida species, particularly C. parapsilosis, C. glabrata, and C. auris further reinforces the importance of AFST and ongoing surveillance. CONCLUSION: Optimal candidemia management increasingly depends on individualized antifungal strategies, integration of RDTs and AFST, earlier species-directed therapy transitions, and selective evaluation for metastatic complications. Future studies are needed to better define uncomplicated candidemia, optimize treatment duration, and address evolving antifungal resistance.
Reference Key
openalex_W7168052194 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors David B. Cluck, Bryan P. White, Sarah A. Hilzendager, Jonathan H. Ryder, Patrick J. Tu, Amanda Z McPherson, Daniel Rogers, Daniel B. Chastain
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag212
URL
https://doi.org/10.1093/ajhp/zxag212
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.